REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for tough leukemia cases
Disease control TerminatedThis early-stage study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
Promising combo for tough leukemias hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug combo targets tough leukemia in patients with RUNX1 mutation
Disease control TerminatedThis study tested two drugs, omacetaxine and venetoclax, in 24 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to treatment. All participants had a specific genetic change called RUNX1. The goal was to find the best dose and see if t…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Experimental combo targets hard-to-treat blood cancers
Disease control TerminatedThis early-stage study tested two drugs, AZD1775 and belinostat, in 20 adults with certain blood cancers (like acute myeloid leukemia) that came back or didn't respond to prior therapy. The main goal was to find the safest dose and check side effects. The study was stopped early,…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Promising AML combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug combo (magrolimab, azacitidine, and venetoclax) in 110 adults with acute myeloid leukemia (AML) that had come back or not responded to treatment. The goal was to find the best dose and see if the drugs could control the cancer. The trial was stopped e…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:39 UTC